Dark Forest Capital Management’s Cytokinetics CYTK Stock Holding History

Dark Forest Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.13M	Buy	36,708 +19,794	+117%	+$1.42M	0.2%	151
2026 Q1	$1.11M	Buy	+16,914	New	+$1.07M	0.1%	336
2024 Q2	–	Sell	-14,437	Closed	-$1.01M	–	703
2024 Q1	$1.01M	Buy	+14,437	New	+$1.12M	0.17%	115
2023 Q3	–	Sell	-21,546	Closed	-$703K	–	1123
2023 Q2	$703K	Buy	21,546 +14,619	+211%	+$541K	0.06%	472
2023 Q1	$244K	Buy	+6,927	New	+$283K	0.06%	308
2021 Q4	–	Sell	-193	Closed	-$7K	–	1505
2021 Q3	$7K	Sell	193 -16	-8%	-$471	﹤0.01%	1040
2021 Q2	$4K	Buy	+209	New	+$4.91K	﹤0.01%	707

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dark Forest Capital Management's CYTK Position: Q2 2026 in Review

Dark Forest Capital Management increased its Cytokinetics (CYTK) stake by 117% in Q2 2026, buying an estimated $1.42M and bringing the position to 36,708 shares worth $3.13M. The position accounts for 0.2% of the portfolio, ranked #151.

Dark Forest Capital Management first reported a position in CYTK in Q2 2021 and has held it in 7 quarters since. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Dark Forest Capital Management held 36,708 shares of Cytokinetics worth $3.13M as of Q2 2026.
Dark Forest Capital Management bought 19,794 Cytokinetics shares in Q2 2026, an estimated $1.42M.
Cytokinetics made up 0.2% of Dark Forest Capital Management's portfolio in Q2 2026, its #151 holding.
Dark Forest Capital Management first reported a position in Cytokinetics in Q2 2021 and has held it in 7 quarters since.
483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Dark Forest Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.